Sign in to continue:

Tuesday, April 21st, 2026

OFG Bancorp 2025 10-K/A Filing: Amendment Details, Company Information, and SEC XBRL Report

OFG Bancorp Files Amendment to Annual Report: Correction to Cover Page on Well-Known Seasoned Issuer Status

Key Highlights:

  • OFG Bancorp has filed Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
  • The amendment was made solely to correct the cover page regarding the company’s status as a “well-known seasoned issuer” (WKSI).
  • The original 10-K, filed on February 25, 2026, mistakenly indicated that OFG Bancorp was a WKSI. The amendment clarifies that OFG Bancorp is NOT a well-known seasoned issuer under Rule 405 of the Securities Act.
  • No other changes, updates, or corrections have been made to the original filing, financial data, or exhibits.

Investor-Relevant Details:

  • Shareholder Information: The amendment does not alter any financial statements, business operations, or forward-looking statements. It is strictly administrative in nature.
  • Potential Price Sensitivity: The correction regarding WKSI status may affect perceptions of the company’s eligibility for certain capital market privileges, such as expedited SEC review processes and automatic shelf registration. Investors should be aware this could impact OFG Bancorp’s ability to raise capital quickly or efficiently compared to WKSI peers.
  • Stock Information: As of January 31, 2026, OFG Bancorp had 43,063,277 common shares outstanding (par value \$1.00 per share), trading under the ticker OFG on the New York Stock Exchange.
  • Public Float: The aggregate market value of public float was approximately \$1.915 billion, based on the closing price of \$42.80 per share.
  • Other Compliance and Governance: OFG Bancorp confirms it is not a shell company, is not an emerging growth company, and has filed all required reports under Section 13 or 15(d) of the Securities Exchange Act of 1934. Auditor attestation of internal controls under Section 404(b) of the Sarbanes-Oxley Act was also affirmed.
  • Proxy Statement Incorporation: Portions of the company’s definitive proxy statement for the 2026 annual meeting of shareholders are incorporated by reference in response to Items 10–14 of Part III of the 10-K/A.

What Shareholders Should Know:

  • This amendment is not a financial restatement and does not reflect any change in the company’s financial or operational outlook.
  • There is no impact on earnings, assets, liabilities, or previously reported results. The amendment solely corrects an administrative error regarding the company’s SEC filer status.
  • Investors should note that OFG Bancorp’s WKSI status may affect its capital-raising flexibility, but otherwise, the company continues to comply with all SEC requirements and remains listed on the NYSE.

Conclusion:

While this amendment does not alter OFG Bancorp’s financial statements or business outlook, it is important for investors to recognize the correction in WKSI status. This administrative update could affect perceptions about the company’s ability to access capital markets expediently, though there are no immediate financial implications. Investors are advised to monitor further filings for any material changes in business strategy, capital structure, or regulatory compliance.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to conduct their own research and consult with financial advisors before making investment decisions. The information herein is based on the latest SEC filings and may be subject to change.

View OFG BANCORP Historical chart here



FRP Holdings, Inc. 2025 Annual Report: Risk Factors, Financial Controls, and Corporate Governance Overview

FRP Holdings, Inc. Releases 2025 Annual Report: Key Insights...

Genie Energy Ltd. (GNE) Files Form 8-K Reporting Preliminary 2025 Results, Company Information, and Key Disclosures

Genie Energy Announces Preliminary 2025 Financial Results an...

Gossamer Bio 2025 Annual Report: Seralutinib PAH Clinical Development, FDA Path, and Regulatory Strategy Insights

Gossamer Bio, Inc. 2025 Annual Report: Key Highlights for In...

   Ad

Join Our Investing Seminar

Limited seats available — Reserve your spot today